Disease · EFO_0006566
dysplastic oral keratinocyte
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. dysplastic oral keratinocyte. Diseases, record EFO_0006566. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0006566
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- dysplastic oral keratinocyte
- Open Targets ID
- EFO_0006566
- Other names
- oral cavity dysplasia, oral epithelial dysplasia, premalignant oral lesion, premalignant oral lesions
- Highest stage of its drugs
- Phase 2, for 4 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CELECOXIB | CHEMBL118 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AVELUMAB | CHEMBL3833373 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IMIQUIMOD | CHEMBL1282 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 other | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 1 | Peroxisome proliferator-activated receptor gamma agonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| PTGS2 | Prostaglandin G/H synthase 2 | 1 | Cyclooxygenase-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| TLR7 | Toll-like receptor 7 | 1 | Toll-like receptor 7 agonist | Phase 1/2 | https://conductscience.org/library/genes/51284 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00951379 | Pioglitazone for Oral Premalignant Lesions | Phase 2 | 52 | 2016-04-06 | Oral Leukoplakia | PIOGLITAZONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04504552 | Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions | Phase 2 | 240 | Oral Premalignant Lesions | AVELUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06561087 | Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions | Phase 2 | 45 | Premalignant Lesion | NIVOLUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00036283 | Chemoprevention of Oral Premalignant Lesions | Phase 2 | 42 | Precancerous Conditions | CELECOXIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07210775 | Topical Imiquimod Treatment of Oral Dysplasia | Phase 1/2 | 20 | Oral Dysplasia, Leukoplakia Oral, Leukoplakia | IMIQUIMOD | Its record names the disease | ClinicalTrials.gov | |
| NCT05327270 | Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | Phase 1 | 18 | Head and Neck Cancer | NIVOLUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00014404 | Celecoxib in Treating Patients With Precancerous Lesions of the Mouth | Phase 2 | Head and Neck Cancer | CELECOXIB | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Arm I (Pioglitazone Hydrochloride) vs Arm II (Placebo): serious adverse events | 3 of 27 | 1 of 25 | 52 | NCT00951379 |
Source Trial comparisons
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0006566
GET https://conductscience.org/api/diseases/v1/EFO_0006566/drugs